Investigator Sponsored Studies, grants and sponsorships
Supports independent research and education advancing scientific knowledge and patient care in cystic fibrosis, pain, IgA nephropathy, beta thalassemia, sickle cell disease, and related serious conditions.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (Cystic fibrosis, Pain, IgA nephropathy) | RFP window (Beta thalassemia, Sickle cell disease; currently closed)
Funding Amounts: No fixed cap; requests should represent fair market value and typically not exceed 30% of the organization's annual budget per year.
Summary: Supports independent research, medical education, and sponsorships advancing care and knowledge in cystic fibrosis and other serious diseases.
Key Information: All requests must be submitted in English and at least 60 days before the event/start date.
Description
Vertex Pharmaceuticals offers a broad external funding program to support independent scientific research, medical education, patient advocacy, and organizational sponsorships. The program is designed to advance the understanding and care of cystic fibrosis, pain (U.S. only), IgA nephropathy, beta thalassemia, sickle cell disease, and related serious diseases. Funding is available for investigator-sponsored studies (ISS), educational initiatives, and sponsorships of relevant events or programs. Vertex prioritizes projects that align with its therapeutic focus and have the potential to impact patient outcomes or further scientific knowledge.
